Frontiers in Immunology (Jun 2022)
mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273
- Alexander C. Dowell,
- Annabel A. Powell,
- Chris Davis,
- Sam Scott,
- Nicola Logan,
- Brian J. Willett,
- Rachel Bruton,
- Morenike Ayodele,
- Elizabeth Jinks,
- Juliet Gunn,
- Eliska Spalkova,
- Panagiota Sylla,
- Samantha M. Nicol,
- Jianmin Zuo,
- Georgina Ireland,
- Ifeanyichukwu Okike,
- Ifeanyichukwu Okike,
- Frances Baawuah,
- Joanne Beckmann,
- Shazaad Ahmad,
- Joanna Garstang,
- Andrew J. Brent,
- Andrew J. Brent,
- Bernadette Brent,
- Marie White,
- Aedin Collins,
- Francesca Davis,
- Ming Lim,
- Ming Lim,
- Jonathan Cohen,
- Julia Kenny,
- Julia Kenny,
- Ezra Linley,
- John Poh,
- Gayatri Amirthalingam,
- Kevin Brown,
- Mary E. Ramsay,
- Rafaq Azad,
- John Wright,
- Dagmar Waiblinger,
- Paul Moss,
- Shamez N. Ladhani,
- Shamez N. Ladhani
Affiliations
- Alexander C. Dowell
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Annabel A. Powell
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Chris Davis
- Medical Research Council (MRC)-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
- Sam Scott
- Medical Research Council (MRC)-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
- Nicola Logan
- Medical Research Council (MRC)-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
- Brian J. Willett
- Medical Research Council (MRC)-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
- Rachel Bruton
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Morenike Ayodele
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Elizabeth Jinks
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Juliet Gunn
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Eliska Spalkova
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Panagiota Sylla
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Samantha M. Nicol
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Jianmin Zuo
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Georgina Ireland
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Ifeanyichukwu Okike
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Ifeanyichukwu Okike
- University Hospitals of Derby and Burton National Health Service (NHS) Foundation Trust, Derby, United Kingdom
- Frances Baawuah
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Joanne Beckmann
- East London National Health Service (NHS) Foundation Trust, London, United Kingdom
- Shazaad Ahmad
- Manchester University National Health Service (NHS) Foundation Trust, Manchester, United Kingdom
- Joanna Garstang
- Birmingham Community Healthcare National Health Service (NHS) Trust, Aston, United Kingdom
- Andrew J. Brent
- Nuffield Department of Medicine, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom
- Andrew J. Brent
- University of Oxford, Oxford, United Kingdom
- Bernadette Brent
- Nuffield Department of Medicine, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom
- Marie White
- 0Department of General Paediatrics, Evelina London Children’s Hospital, London, United Kingdom
- Aedin Collins
- 1The National Children’s Hospital, Tallaght University Hospital, Dublin, Ireland
- Francesca Davis
- 0Department of General Paediatrics, Evelina London Children’s Hospital, London, United Kingdom
- Ming Lim
- 2Children’s Neurosciences, Evelina London Children’s Hospital at Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, King’s Health Partners Academic Health Science Centre, London, United Kingdom
- Ming Lim
- 3Department Women and Children’s Health, School of Life Course Sciences (SoLCS), King’s College London, London, United Kingdom
- Jonathan Cohen
- 4Department of Paediatric Infectious Diseases and Immunology Evelina London Children’s Hospital, London, United Kingdom
- Julia Kenny
- 3Department Women and Children’s Health, School of Life Course Sciences (SoLCS), King’s College London, London, United Kingdom
- Julia Kenny
- 4Department of Paediatric Infectious Diseases and Immunology Evelina London Children’s Hospital, London, United Kingdom
- Ezra Linley
- 5United Kingdom (UK) Health Security Agency, Manchester Royal Infirmary, Manchester, United Kingdom
- John Poh
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Gayatri Amirthalingam
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Kevin Brown
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Mary E. Ramsay
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Rafaq Azad
- 6Bradford Institute for Health Research, Bradford Teaching Hospitals National Health Service (NHS) Foundation Trust, Bradford, United Kingdom
- John Wright
- 6Bradford Institute for Health Research, Bradford Teaching Hospitals National Health Service (NHS) Foundation Trust, Bradford, United Kingdom
- Dagmar Waiblinger
- 6Bradford Institute for Health Research, Bradford Teaching Hospitals National Health Service (NHS) Foundation Trust, Bradford, United Kingdom
- Paul Moss
- Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Shamez N. Ladhani
- Immunisation and Vaccine Preventable Diseases Division, United Kingdom (UK) Health Security Agency, London, United Kingdom
- Shamez N. Ladhani
- 7Paediatric Infectious Diseases Research Group, St. George’s University of London, London, United Kingdom
- DOI
- https://doi.org/10.3389/fimmu.2022.882515
- Journal volume & issue
-
Vol. 13
Abstract
Children and adolescents generally experience mild COVID-19. However, those with underlying physical health conditions are at a significantly increased risk of severe disease. Here, we present a comprehensive analysis of antibody and cellular responses in adolescents with severe neuro-disabilities who received COVID-19 vaccination with either ChAdOx1 (n=6) or an mRNA vaccine (mRNA-1273, n=8, BNT162b2, n=1). Strong immune responses were observed after vaccination and antibody levels and neutralisation titres were both higher after two doses. Both measures were also higher after mRNA vaccination and were further enhanced by prior natural infection where one vaccine dose was sufficient to generate peak antibody response. Robust T-cell responses were generated after dual vaccination and were also higher following mRNA vaccination. Early T-cells were characterised by a dominant effector-memory CD4+ T-cell population with a type-1 cytokine signature with additional production of IL-10. Antibody levels were well-maintained for at least 3 months after vaccination and 3 of 4 donors showed measurable neutralisation titres against the Omicron variant. T-cell responses also remained robust, with generation of a central/stem cell memory pool and showed strong reactivity against Omicron spike. These data demonstrate that COVID-19 vaccines display strong immunogenicity in adolescents and that dual vaccination, or single vaccination following prior infection, generate higher immune responses than seen after natural infection and develop activity against Omicron. Initial evidence suggests that mRNA vaccination elicits stronger immune responses than adenoviral delivery, although the latter is also higher than seen in adult populations. COVID-19 vaccines are therefore highly immunogenic in high-risk adolescents and dual vaccination might be able to provide relative protection against the Omicron variant that is currently globally dominant.
Keywords